GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofarm SA (BSE:BIO) » Definitions » EV-to-EBITDA

Biofarm (BSE:BIO) EV-to-EBITDA : 7.90 (As of Jun. 06, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Biofarm EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biofarm's enterprise value is lei651.8 Mil. Biofarm's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was lei82.5 Mil. Therefore, Biofarm's EV-to-EBITDA for today is 7.90.

The historical rank and industry rank for Biofarm's EV-to-EBITDA or its related term are showing as below:

BSE:BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.92   Med: 5.68   Max: 13.87
Current: 6.9

During the past 13 years, the highest EV-to-EBITDA of Biofarm was 13.87. The lowest was -0.92. And the median was 5.68.

BSE:BIO's EV-to-EBITDA is ranked better than
80.53% of 714 companies
in the Drug Manufacturers industry
Industry Median: 14.065 vs BSE:BIO: 6.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Biofarm's stock price is lei0.77. Biofarm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was lei0.066. Therefore, Biofarm's PE Ratio for today is 11.67.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biofarm EV-to-EBITDA Historical Data

The historical data trend for Biofarm's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofarm EV-to-EBITDA Chart

Biofarm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.74 4.57 8.63 5.56 7.93

Biofarm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.98 5.45 6.91 - -

Competitive Comparison of Biofarm's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofarm's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofarm's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biofarm's EV-to-EBITDA falls into.



Biofarm EV-to-EBITDA Calculation

Biofarm's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=651.767/82.487
=7.90

Biofarm's current Enterprise Value is lei651.8 Mil.
Biofarm's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was lei82.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofarm  (BSE:BIO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biofarm's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.77/0.066
=11.67

Biofarm's share price for today is lei0.77.
Biofarm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.066.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biofarm EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biofarm's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofarm (BSE:BIO) Business Description

Traded in Other Exchanges
N/A
Address
99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.